PuraPharm Corporation Limited announced that with effect from 20 November 2023, Dr. Norimoto Hisayoshi ("Dr. Norimoto") is appointed as the chief executive officer of Purapharm Japan Corporation, a wholly-owned subsidiary of the Company incorporated in Japan. Dr. Norimoto will be in charge of the operation of the Group in the Japanese market. Following the rotation of position of Dr. Norimoto, Dr. Norimoto ceased to be an executive Director on 20 November 2023 as his three years' term of office under the service agreement entered into between the Company and Dr. Norimoto had expired.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.78 HKD | 0.00% | +1.30% | -13.33% |
04-01 | PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9% | MT |
03-28 | PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.33% | 39.44M | |
+40.09% | 6.16B | |
-16.34% | 4.46B | |
-7.11% | 3.27B | |
+5.14% | 3.2B | |
-0.18% | 2.6B | |
+47.93% | 1.98B | |
-7.15% | 1.7B | |
+0.67% | 1.66B | |
-8.73% | 1.61B |
- Stock Market
- Equities
- 1498 Stock
- News PuraPharm Corporation Limited
- PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director